関連する実験動画
Updated: Jan 24, 2026

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
Published on: May 31, 2024
シャガス病感受性と慢性シャガス心筋症重症度に関連する循環マイクロRNAのトランスクリプトーム解析
Eric Henrique Roma1, Fabielle Marques-Santos1,2, Alinne Rangel Dos Santos Renzetti1,2
1Laboratório de Imunologia e Imunogenética em Doenças Infeciosas - Instituto Nacional de Infectologia Evandro Chagas - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Background:
Chagas disease (ChD), a major public health concern in Latin America, requires better understanding of molecular mechanisms driving disease progression and identifying biomarkers.
Objective:
We investigated circulating microRNAs associated with ChD susceptibility and chronic Chagas cardiomyopathy (CCC) progression.
Methods:
In a cross-sectional study with 150 ChD patients (46 indeterminate, 104 CCC) and 42 non-ChD controls, we performed microRNA sequencing, and differentiated expressed microRNAs (DEMs) were submitted to in silico functional analyses.
Results:
We identified 40 DEMs between ChD patients and controls, highlighting upregulated miR-143-3p and miR-223-3p, and downregulated miR-486-5p and miR-3960 in ChD patients. These miRNAs showed involvement in immune response and cardiovascular signaling pathways. MiR-6734-5p, miR-1285-5p, miR-10527-5p and miR-1228-5p tended to be upregulated, while miR-30c-3p tended to be downregulated in severe compared to mild CCC patients.
Conclusion:
This study provides evidence for specific microRNA dysregulation in ChD, highlighting their potential as biomarkers of ChD susceptibility and CCC severity.
関連する概念動画
MicroRNAs
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Kidney Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

